Dr George Wiggins
Women at high-risk of breast cancer are in need of new and effective prevention strategies.
Extracellular Vesicles as Inter-Cellular Communicators in Fat Graft Retention
Dr Kirsty Danielson
Breast reconstruction is an important part of the treatment process for women with breast cancer.
Stopping Breast Cancer Evolution: Evaluation of APOBEC3 Inhibitors in Live Cells
Associate Professor Vyacheslav Filichev
Drug resistance is a serious barrier to the treatment of breast cancer, leading to metastasis and cancer reoccurrences.
Exploring a Novel Therapy to Reduce Breast Cancer Risk in High-risk Individuals
Dr Vanessa Lattimore
The ideal strategy for controlling and reducing the social impact of disease is effective prevention.
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Dr Gavin Harris
Digital pathology is the reviewing of tissue slides on a computer monitor rather than using microscopes.
Validation Of Predictive Biomarkers For T-DM1 Activity In HER2+ Breast Cancer
Dr Barbara Lipert
The antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) extends the survival of HER2-positive metastatic breast cancer patients.
Analysis Of Full-length Transcripts For Variant Classification In Breast Cancer
Dr Logan Walker
The future of successful genetic screening in New Zealand requires increased sensitivity and specificity of tests, and informed clinical management for high-risk breast cancer families.
Validation Of A Liquid Biopsy To Predict Recurrence In NZ Breast Cancer Patients
Dr Annette Lasham
Early detection of breast cancer recurrence is critical for saving lives. We have identified two molecules, found in the blood of 250 patients at the time of surgery for breast cancer, that were very good at predicting which of these women would have a relapse before five years.
Preventing Breast Cancer Metastasis With Conjugate Vaccines Targeting Human HER2
Dr Robert Weinkove
The aim of this novel and ambitious project is to develop potent new vaccines with potential to prevent recurrence of HER2 positive breast cancer.
Targeting HIF-1 In Triple Negative Breast Cancer Using Glutaminase Inhibitors
Dr Dean Singleton
It is now understood that Triple Negative breast cancer has many biologic nuances and a heterogeneity not previously understood.